Oncobiologics raises $31m for biosimilars; RaNA, Ra, SutroVax add VC cash
This article was originally published in Scrip
Executive Summary
Smart companies are raising money to advance drug development programs while investors are pouring cash into the biotechnology industry. The latest to raise private capital: Oncobiologics, Ra Pharmaceuticals, RaNA Therapeutics and SutroVax.
You may also be interested in...
IPO Update: Returns Rebound As June Sees Its First New Biopharma Offering
MeiraGTx was the first to go public in the US in June after six drug developer IPOs launched in May. With returns for this year's first-time biopharma offerings more than doubling from 9% at the end of April to 23.6% as of June 8, four new companies have filed and six have set terms for future IPOs.
Finance Watch: Raising Cash Before A Trump Slump, La Jolla Nabs $125m, Akcea Eyes $100m IPO
La Jolla Pharmaceutical grossed $125m, Inspyr Therapeutics signs a deal to raise up to $100m, Ionis's Akcea makes $100m IPO plans, and $64m in cash for SutroVax tops recent venture capital rounds.
Sanofi's Biosimilars Deal With JHL Confirms Growing Trend In China
Sanofi is joining the biosimilars trend to tap into China through a local partnership with Taiwan's JHL Biotech, initially focusing on rituximab, a biosimilar product that has great market potential but strong competition in development by domestic peers.